---
layout: default
title: Prednisolone Acetate
parent: 僅模型預測 (L5)
nav_order: 813
evidence_level: L5
indication_count: 10
---

# Prednisolone Acetate
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Prednisolone Acetate: From Ocular Inflammation to Chronic Follicular Conjunctivitis

## One-Sentence Summary

> Prednisolone acetate is a topical corticosteroid conventionally used to control ocular surface inflammation (e.g., allergic conjunctivitis, uveitis, post-operative inflammation).
> The TxGNN model predicts it may be effective for **Chronic Follicular Conjunctivitis**,
> but this is currently supported by only **1 indirectly related clinical trial** and **1 case report**, placing the evidence at a preliminary, hypothesis-generating stage.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not specified in the evidence pack; no Singapore registration on file. Known pharmacological use: topical anti-inflammatory therapy for ocular conditions |
| Predicted New Indication | Chronic Follicular Conjunctivitis |
| TxGNN Prediction Score | 99.74% |
| Evidence Level | L4 |
| Singapore Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism-of-action data for this DrugBank entry is not available in the evidence pack. Based on known pharmacology, prednisolone acetate is a topical ophthalmic corticosteroid that suppresses inflammatory mediator release (e.g., phospholipase A2/arachidonic acid cascade) at the ocular surface. Its efficacy in inflammatory conjunctival and uveitic conditions is well established in clinical practice, and mechanistically this anti-inflammatory action could extend to other inflammatory conjunctival diseases.

Chronic follicular conjunctivitis, however, is an etiologically heterogeneous condition — causes range from viral and chlamydial infection to drug toxicity and immune-mediated inflammation. The repurposing rationale in the evidence pack explicitly flags this: if the underlying pathology in a given patient is immune/inflammatory, topical corticosteroids have a plausible anti-inflammatory rationale; but if the cause is infectious, steroid monotherapy could delay pathogen-directed treatment or worsen the clinical course. This means applicability is likely subtype-dependent rather than universal.

Supporting this plausibility, several literature entries in the evidence pack already describe off-label or adjunctive use of prednisolone acetate in related inflammatory ocular conditions (e.g., mycoplasma-induced mucositis with conjunctival involvement, suspected allergic conjunctivitis with giant papillae). This suggests the drug is already used empirically at the margins of this disease spectrum, which lends some real-world plausibility to the TxGNN signal even though direct efficacy data for chronic follicular conjunctivitis specifically is lacking.

---

## Clinical Trial Evidence

| Trial Number | Phase | Status | Enrollment | Key Findings |
|---------|------|------|------|---------|
| [NCT04705584](https://clinicaltrials.gov/study/NCT04705584) | NA | Unknown | 180 | Compares topical cyclosporine A 2% vs. tacrolimus 0.3% as steroid-sparing alternatives in resistant spring catarrh (vernal allergic conjunctivitis). Confirms topical steroids are the treatment cornerstone for this allergic conjunctival disorder, but the study population is VKC, not chronic follicular conjunctivitis — relevance graded **C (indirect)**. |

---

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [29801089](https://pubmed.ncbi.nlm.nih.gov/29801089/) | 2018 | Case Report | JAMA Ophthalmology | Describes a case of chronic follicular conjunctivitis in a middle-aged woman; no abstract available, so treatment outcome detail is limited. |

---

## Singapore Market Information

Prednisolone acetate has no registered license in Singapore (0 authorizations on file); market status is **not marketed**. No product name, dosage form, or approved indication text is available for this jurisdiction.

---

## Safety Considerations

Please refer to the package insert for safety information. The evidence pack flags this as a **blocking data gap** (missing TFDA/HSA label warnings and contraindications), which currently prevents a formal Stage 1 safety assessment for this candidate.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
Evidence is limited to one indirectly related clinical trial (studying a different, though related, allergic condition) and a single case report — an L4 evidence level. The drug is not currently registered in Singapore, and a blocking gap in label/safety data prevents any safety pre-assessment.

**To proceed, the following is needed:**
- Official product label with warnings and contraindications (from HSA/TFDA or manufacturer)
- Confirmed mechanism of action (DrugBank or primary pharmacology sources)
- Direct clinical evidence in chronic follicular conjunctivitis, ideally stratified by etiology (infectious vs. immune-mediated), since steroid use may be inappropriate for infectious subtypes
- Confirmation of local (Singapore) market/registration pathway if development is pursued
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

